Publications by authors named "K Mirkovic Kos"

Article Synopsis
  • Immune checkpoint blockade (ICB) is gaining traction in treating advanced cancer patients, but its effects on the immune system and cancer spread in neoadjuvant settings are not fully understood.
  • Tumors can promote the expansion of regulatory T cells (T), which may inhibit ICB effectiveness and contribute to cancer progression.
  • Research shows that depleting T cells during neoadjuvant ICB boosts the immune response, increases survival related to metastasis, and shows that targeting T cells might improve outcomes without necessarily shrinking the primary tumor.
View Article and Find Full Text PDF

Immune checkpoint blockade (ICB) has heralded a new era in cancer therapy. Research into the mechanisms underlying response to ICB has predominantly focused on T cells; however, effective immune responses require tightly regulated crosstalk between innate and adaptive immune cells. Here, we combine unbiased analysis of blood and tumors from metastatic breast cancer patients treated with ICB with mechanistic studies in mouse models of breast cancer.

View Article and Find Full Text PDF

While regulatory T cells (T) and macrophages have been recognized as key orchestrators of cancer-associated immunosuppression, their cellular crosstalk within tumors has been poorly characterized. Here, using spontaneous models for breast cancer, we demonstrate that tumor-associated macrophages (TAMs) contribute to the intratumoral accumulation of T by promoting the conversion of conventional CD4 T cells (T) into T. Mechanistically, two processes were identified that independently contribute to this process.

View Article and Find Full Text PDF

Breast cancer is accompanied by systemic immunosuppression, which facilitates metastasis formation, but how this shapes organotropism of metastasis is poorly understood. Here, we investigate the impact of mammary tumorigenesis on regulatory T cells (T) in distant organs and how this affects multi-organ metastatic disease. Using a preclinical mouse mammary tumor model that recapitulates human metastatic breast cancer, we observe systemic accumulation of activated, highly immunosuppressive T during primary tumor growth.

View Article and Find Full Text PDF